Phase II Trial of Nab-paclitaxel Plus S-1 in First-line Treatment of Patients With Advanced Pancreatic Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Dec 2018
Price : $35 *
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms NAPSPAC
- 06 Jun 2017 Results assessing the efficacy and safety of nab-paclitaxel plus S-1 as first-line treatment in patients with locally advanced and metastatic pancreatic adenocarcinoma, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 21 Dec 2016 Planned End Date changed from 1 Dec 2015 to 1 May 2017.
- 21 Dec 2016 Status changed from recruiting to active, no longer recruiting.